Lupus Drug Development

There hasn't been a new drug approved for lupus in nearly 50 years, and current options are often as toxic and damaging as the disease itself.

But unlike a decade or two ago, there is now real hope that safe new treatments will soon be introduced and approved by the FDA.

Today there is “cautious optimism” on new drugs for lupus—see perspectives from experts at a recent LRI scientific conference.

But who holds the keys to spurring new lupus therapeutics? Read about one expert’s perspective.

Why are clinical trials so vital to moving lupus treatments forward? See how trial, doctor, and participant can make it happen

Latest News on Lupus Drug Development

• UPDATE 2-UCB, Immunomedics drug shows promise for lupus
• Lupus drug passes key test, researchers say
• Lupus Research Institute Highly Encouraged by Benlysta™ Trial Results
• Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for Benlysta™
• HGS Hoping to Survive Final Test of Lupus Drug
• Human Genome's Lupus Drug Shows Success in Trials; Shares Jump
• Human Genome Sciences - Racing To Cure Lupus
• UM Spinoff Lycera To Receive $36 Million Financing
• Trubion Pharmaceuticals, Inc. Announces Initiation Of Phase 1 Study Of SBI-087 For The Treatment Of Systemic Lupus Erythematosus (SLE)
• Cephalon pays $30M to license lupus drug
• Human Genome Sciences Reports Substantial Progress Toward Commercialization
• BioMarin and La Jolla enter Riquent license pact
• La Jolla Pharmaceutical enters deal on lupus drug
• Newly refined antibody therapy may be potent treatment for autoimmune diseases
• Aspreva says FDA fast-tracks CellCept lupus drug
• Genes Dictate Response to Lupus Drugs
• On December 18th the FDA warned of safety concerns regarding the treatment of lupus patients with Rituxan.
  People with lupus who have questions or concerns should contact their doctor.
  Press Release: FDA warns of safety concern regarding Rituxan in new patient population
  FDA Public Health Advisory: Life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (Rituximab) treatment
• Genentech's Next Act
• Drug pipeline suggests glimmer of hope for SLE sufferers
• B Cells Move to Centre Stage: Novel Opportunities for Autoimmune Disease Treatment
• Biotechnology Continues to Break Ground in Autoimmune and Inflammatory Disease Treatment